Voelkel-Johnson C - Search Results

1

Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction.

Burke B, Eden C, Perez C, Belshoff A, Hart S, Plaza-Rojas L, Delos Reyes M, Prajapati K, Voelkel-Johnson C, Henry E, Gupta G, Guevara-Patiño J. Burke B, et al. Front Oncol. 2020 May 15;10:699. doi: 10.3389/fonc.2020.00699. eCollection 2020. Front Oncol. 2020. PMID: 32500025 Free PMC article.

2

The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.

Kasman L, Lu P, Voelkel-Johnson C. Kasman L, et al. Cancer Gene Ther. 2007 Mar;14(3):327-34. doi: 10.1038/sj.cgt.7701017. Epub 2006 Dec 22. Cancer Gene Ther. 2007. PMID: 17186014

3

The role of protein synthesis in cell cycling and cancer.

White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. White-Gilbertson S, et al. Mol Oncol. 2009 Dec;3(5-6):402-8. doi: 10.1016/j.molonc.2009.05.003. Epub 2009 Jun 11. Mol Oncol. 2009. PMID: 19546037 Free PMC article. Review.

4

Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells.

Kasman L, Onicescu G, Voelkel-Johnson C. Kasman L, et al. Prostate Cancer. 2012;2012:137163. doi: 10.1155/2012/137163. Epub 2012 Jan 12. Prostate Cancer. 2012. PMID: 22288017 Free PMC article.

5

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.

Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. Sudarshan S, et al. Cancer Gene Ther. 2005 Jan;12(1):12-8. doi: 10.1038/sj.cgt.7700746. Cancer Gene Ther. 2005. PMID: 15514684

6

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.

El-Zawahry A, McKillop J, Voelkel-Johnson C. El-Zawahry A, et al. BMC Cancer. 2005 Jan 7;5:2. doi: 10.1186/1471-2407-5-2. BMC Cancer. 2005. PMID: 15638938 Free PMC article.

7

In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.

El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C. El-Zawahry A, et al. Cancer Gene Ther. 2006 Mar;13(3):281-9. doi: 10.1038/sj.cgt.7700905. Cancer Gene Ther. 2006. PMID: 16167063

8

Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins.

White-Gilbertson SJ, Kasman L, McKillop J, Tirodkar T, Lu P, Voelkel-Johnson C. White-Gilbertson SJ, et al. J Urol. 2009 Sep;182(3):1178-85. doi: 10.1016/j.juro.2009.05.005. Epub 2009 Jul 21. J Urol. 2009. PMID: 19625063 Free PMC article.

9

Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.

Kasman LM, Barua S, Lu P, Rege K, Voelkel-Johnson C. Kasman LM, et al. Mol Pharm. 2009 Sep-Oct;6(5):1612-9. doi: 10.1021/mp9000958. Mol Pharm. 2009. PMID: 19655763 Free PMC article.

10

TRAIL-mediated signaling in prostate, bladder and renal cancer.

Voelkel-Johnson C. Voelkel-Johnson C. Nat Rev Urol. 2011 Jun 14;8(8):417-27. doi: 10.1038/nrurol.2011.81. Nat Rev Urol. 2011. PMID: 21670755 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters